Sapheon raises $3.6 million in a convertible debt offering as it pursues pre-market approval from the FDA for its VenaSeal varicose vein treatment.
Sapheon raised $3.6 million of a hoped-for $10 million in a convertible debt offering it plans to use as working capital, according to a regulatory filing.
Forty-nine unnamed investors participated in the round for Morrisville, N.C.-based Sapheon, which makes the VenaSeal device for treating varicose veins, according to the filing.
Kardiametrics sues a raft of big-name medical device companies, including Boston Scientific, Abbott and Covidien, alleging infringement of its patents for blood clot protection devices.
AngioDynamics wins CE Mark approval on the European Union for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit.
AngioDynamics (NSDQ:ANGO) said it won CE Mark approval in the European Union for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit.
Minnesota's Cardiovascular Systems gets a Wall Street boost after winning FDA approval for its Diamondback 360 Coronary Orbital Atherectomy System.
Medtronic puts its Export Advance thrombectomy catheter on the market in the U.S.
Medtronic (NYSE:MDT) said it's launching the Export Advance aspiration catheter for removing clots from blood vessels now that the FDA has cleared the device.
The Export Advance device is designed to provide improved deliverability and kink resistance during thrombectomies, according to a press release.
Sapheon says it's filed the 1st module in its pre-market approval application to the FDA for its VenaSeal Sapheon device, designed to treat varicose veins.
Sapheon Inc. said it's taken the 1st step toward getting its VenaSeal Sapheon varicose vein device on the U.S. market, filing the 1st module in its pre-market approval application with the FDA.
"The submission places Sapheon on track for timely FDA review and expected product launch in the 1st half of 2015," according to a press release.
Burlington, Mass.-based vascular device maker LeMaitre Vascular acquires InaVein and its varicose vein removal technology.
LeMaitre Vascular (NSDQ:LMAT) is jumping into the varicose vein removal business with a $2.5 million buyout of InaVein. The Burlington, Mass.-based vascular device maker snatched up InaVein for more than 100% more than the company's 2012 sales, according to a company statement.